Previous research by Ambrogio et al. (46) highlighted that “KRAS” dimerization enhances the survival of both human and murine KRAS mutant LUAD tumor cells possessing wild-type KRAS, explaining the observed resistance to MEK inhibition. This evidence concerns the gene MAP2K7 and neoplasm.